Tricida (TCDA) IPO Opens 32% Higher

Today's IPO for Tricida (NASDAQ: TCDA) opened for trading at $25 after pricing 11,700,000 shares of its common stock at $19.

Tricida has granted to the underwriters a 30-day option to purchase up to 1,755,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.

You May Also Be Interested In

• Scribe Therapeutics raises $155.51M in IPO on Nasdaq
• Notice to Long-Term Shareholders of EquipmentShare.com, Inc. (NASDAQ: EQPT); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation Inc. (NYSE:
• Morningstar Completes Rebrand of CRSP Market Indexes to Morningstar Market Indexes